Other hot topics included new data on LAAO and conduction-system pacing, plus the go-ahead for ablation in ASCs.

After claiming its approval in Europe earlier this year, Abbott has secured the FDA’s go-ahead for its Volt pulsed field ablation system for irregular heart rhythms, a step forward in an | With the U.

Sarawak has reached a new milestone in advanced cardiac care with the successful completion of the first EPi-Sense hybrid ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond ...

Abbott has announced the company has received approval from the U.S. Food and Drug Administration (FDA) for its Volt PFA ...

Dr. Nassir Marrouche is director of the Heart and Vascular Institute at Tulane University with a subspecialty in ...

The US Food and Drug Administration (FDA) has granted approval for Abbott’s Volt PFA System, expanding treatment options for ...

US FDA approves Abbott's Volt PFA System to treat patients with atrial fibrillation: Abbott Park, Illinois Wednesday, December 24, 2025, 12:00 Hrs [IST] Abbott, is a global health ...

Boston Scientific ($BSX) announced an update on their ongoing clinical study. Study OverviewThis global Boston Scientific trial, officially titled ...

Abbott can now compete with Medtronic, Boston Scientific and J&J in the U.S. for the fast-growing pulsed field ablation market.

ABT wins FDA approval for its Volt PFA System for AFib, paving the way for U.S. launches and EU expansion after earlier CE Mark clearance.

Boston Scientific Corporation is rated a Hold with double-digit revenue growth and margin expansion. Learn more about BSX ...